Want to see HK:6872 full AI Analyst Report?
Top Page
TenNor Therapeutics Suzhou Ltd. Class H
(6872)
Select Model
Select Model
Rating:41Neutral
Price Target:
$130.00
Action:Reiterated
Date:09/11/26
The score is primarily constrained by weak financial performance: no revenue, persistent losses, and ongoing cash burn despite improved leverage and positive equity in 2025. Technicals add risk with the stock trading well below its 20- and 50-day averages and negative MACD, only partially offset by oversold RSI/Stoch readings. Valuation is further pressured by negative earnings (negative P/E) and no dividend support.
Positive Factors
Modest leverage
Modest leverage provides a stronger financial base than a highly indebted balance sheet and may reduce near-term pressure from debt servicing. The 2025 debt-to-equity position gives management greater flexibility to fund development while limiting the balance-sheet amplification of operating losses.
Negative Factors
No commercial revenue
A three-year absence of reported revenue indicates that commercial traction has not yet been established. Without product sales or operating revenue, the company remains dependent on capital resources to support development, making future financial progress highly dependent on achieving successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest leverage
Modest leverage provides a stronger financial base than a highly indebted balance sheet and may reduce near-term pressure from debt servicing. The 2025 debt-to-equity position gives management greater flexibility to fund development while limiting the balance-sheet amplification of operating losses.
Read all positive factors
TenNor Therapeutics Suzhou Ltd. Class H (6872) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.54B
Dividend YieldN/A
Average Volume (3M)79.47K
Price to Earnings (P/E)―
Beta (1Y)-0.13
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,328,926
10 Day Avg. Volume97,808
30 Day Avg. Volume79,472
Financial Highlights & Ratios
PEG Ratio-12.90
Price to Book (P/B)63.75
Price to Sales (P/S)0.00
P/FCF Ratio-111.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TenNor Therapeutics Suzhou Ltd. Class H Business Overview & Revenue Model
Company Description
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasuteni...
How the Company Makes Money
null...
TenNor Therapeutics Suzhou Ltd. Class H Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| EBITDA | -150.18M | -141.35M | -186.61M |
| Net Income | -153.24M | -145.93M | -191.84M |
Balance Sheet | |||
| Total Assets | 227.04M | 132.89M | 96.05M |
| Cash, Cash Equivalents and Short-Term Investments | 183.76M | 97.82M | 58.11M |
| Total Debt | 28.65M | 53.02M | 59.42M |
| Total Liabilities | 73.18M | 1.03B | 854.96M |
| Stockholders Equity | 153.86M | -898.05M | -758.91M |
Cash Flow | |||
| Free Cash Flow | -87.65M | -48.80M | -98.63M |
| Operating Cash Flow | -87.19M | -48.60M | -98.12M |
| Investing Cash Flow | 2.50M | -185.00K | 70.38M |
| Financing Cash Flow | 170.63M | 88.50M | 4.73M |
TenNor Therapeutics Suzhou Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$20.24B | 22.26 | 12.35% | ― | 117.39% | ― | |
66 Neutral | HK$24.93B | 56.35 | 15.79% | ― | 48.04% | 166.72% | |
52 Neutral | HK$21.51B | -13.86 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$11.63B | -6.89 | -153.78% | ― | 70.26% | -12.79% | |
44 Neutral | HK$16.16B | -7.34 | -179.83% | ― | 385.38% | ― | |
41 Neutral | HK$6.54B | -36.06 | 41.18% | ― | ― | ― |
* Healthcare Sector Average
HK:6872
TenNor Therapeutics Suzhou Ltd. Class H
125.00
-86.00
-40.76%
HK:9688
Zai Lab Ltd
18.94
-6.08
-24.30%
HK:9969
InnoCare Pharma Ltd.
13.54
-4.27
-23.98%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
56.10
30.56
119.66%
HK:6855
Ascentage Pharma Group International
31.38
-44.77
-58.79%
HK:2493
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
20.30
-7.50
-26.98%
TenNor Therapeutics Suzhou Ltd. Class H Corporate Events
TenNor Therapeutics Advances First-in-Class Prosthetic Joint Infection Drug After Positive Phase IIa Data
Sep 7, 2026
TenNor Therapeutics (Suzhou) Limited is a PRC-based biopharmaceutical company developing innovative anti-infective drugs for implant-related complications, led by its candidate rifaquizinone (TNP-2092) for prosthetic joint infection. The company s...
TenNor Therapeutics Narrows Loss and Advances Anti-Infective and CNS Pipeline
Aug 26, 2026
TenNor Therapeutics reported interim results for the six months to 30 June 2026 showing a narrowed loss of RMB64.2 million despite higher research and administrative expenses, supported by a sharp increase in cash and cash equivalents to RMB714.7 ...
TenNor Therapeutics Sets Board Meeting to Review Interim Results and Possible Dividend
Aug 14, 2026
TenNor Therapeutics (Suzhou) Limited has scheduled a board meeting for August 26, 2026 to review and approve its interim results for the six months ended June 30, 2026. The board will also consider the potential declaration of an interim dividend,...
TenNor Therapeutics Wins Unanimous Backing at 2025 Shareholders’ Meeting
Jun 29, 2026
TenNor Therapeutics reported that its 2025 annual shareholders’ meeting was held on June 29, 2026, in Suzhou with shareholders and proxies representing about 32.68% of the company’s H shares. The meeting was chaired by chairman and CEO...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.